Aceso Life Science swings to FY26 profit of HK$336 million; revenue rises 16% to HK$58 million

• Aceso Life Science Group swung to profit of HK$336 million, with earnings per share at HK$0.05.
• Revenue rose 16% to HK$58 million, while loss before tax narrowed to HK$421 million from HK$659 million.
• Net fair value gains turned positive at HK$52 million, reflecting HK$90 million gains on financial assets at FVTPL.
• Other losses widened to HK$325 million due to a HK$325 million loss on disposal of an associate.
• Management highlighted its shift to UK property leasing, with refurbishment under way and completion of lift modernization at 55 Mark Lane, London.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260813-12282253), on August 13, 2026, and is solely responsible for the information contained therein.